A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT00238472
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Type 2 diabetes diagnosed at least 1 year before inclusion
- Blood glucose criteria must be met
- Microalbuminuria criteria must be met
Exclusion Criteria
- Pregnant or nursing females or females of childbearing potential not using a medically approved birth control method
- Blood glucose criteria outside the specified range
- Microalbuminuria criteria outside the specified range
- Serious cardiovascular events within the past 6 months
- Other protocol-defined exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in postprandial glomerular filtration rate at 12 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in fasting morning glomerular filtration rate at 12 weeks Change from baseline in postprandial renal plasma flow at 12 weeks Change from baseline in fasting morning renal plasma flow at 12 weeks Change from baseline in adjusted 2-hour postprandial glucose at 12 weeks Change in insulin AUC (0-240 minutes) at 12 weeks